



Paris, January 9<sup>th</sup>, 2020

Dear Association for Creatine Deficiencies,

Aloïse, Henri and I are pleased to introduce you to Ceres Brain Therapeutics, a company that we co-founded recently with the aim of developing treatments for rare cerebral diseases.

Ceres Brain, a spin-off from the French alternative energies and Atomic Energy Commission (CEA), one of the most innovative academic research organizations in Europe, will work closely with the research team of Aloïse Mabondzo, a leading researcher in cerebrovascular pharmacology.

Ceres' first product, CBT 101, tackles the challenge of Creatine Transporter Deficiency through a creatine derivative that increases the cerebral level of creatine and improves cognition after multiple dosing in knock out mice.

Ceres Brain is committed to focus its resources to advance CBT 101 development over coming years in order to provide CTD patients with a therapeutic solution to deliver creatine in the brain.

Please find our latest news on <https://www.linkedin.com/company/ceres-brain-therapeutics/>



Aloïse Mabondzo, PhD, CSO “As Neuroscientist, I aim to bridge the gap between experimental research and clinical therapy for cerebral diseases. I am proud to be part of the team as we hope to find a treatment for CTD patients”.



Henri Bénech, PharmD, PhD, COO “As a pharmacist, and COO of CERES BRAIN, I will be committed to efficiently setting up the next steps of CBT 101's development. My colleagues and I look forward to making every effort to rapidly offer a therapeutics solution to patients in the future.”



## CERES BRAIN Therapeutics



Thomas Joudinaud, MD, PhD, CEO “As a Medical Doctor and CEO of the company, I am very proud to be part of such a team. Bringing solutions to patients with cerebral disease is our mission. I look forward to the next steps of our development of CBT 101 and I hope that Ceres will successfully develop therapeutic solutions for CTD patients”